Interestingly, in a recent clinical study, DNA-PK inhibitors, including M3814 at dosages from 110 μM to 320 μM, were found to be safe and highly effective as potential anti-cancer drugs [88,89,90,91,92,93,94,95,96,97,98], validating the safety of these agents for human use [90]. The gene discussed is PRKDC; the disease is cancer.